What is the mission of Mirum Pharma?
Mirum Pharmaceuticals is driven by a patient-centric mission focused on transforming and improving the lives of individuals suffering from rare, debilitating diseases, with a specialized emphasis on orphan liver conditions affecting both pediatric and adult populations. The company is dedicated to pioneering innovative, groundbreaking therapies that bridge critical gaps in unmet medical needs. By pushing the boundaries of scientific research, advancing clinical development pipelines, and working collaboratively with healthcare professionals and patient communities, the organization strives to deliver remarkable medical solutions and hope to patients worldwide.
Related FAQs
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing novel, life-changing therapies for patients suffering from rare, debilitating liver diseases and orphan conditions.
Mirum Pharmaceuticals operates as a commercial-stage biopharmaceutical company focusing on rare and orphan diseases, carrying specific clinical and commercial risk factors.
Equity research analysts evaluate Mirum Pharmaceuticals, Inc. with strong, highly favorable long-term growth prospects, propelled by surging global demand for its specialized rare liver disease therapies.
Equity research analysts tracking Mirum Pharmaceuticals (NASDAQ: MIRM) generally express strong bullish sentiment, issuing consensus buy ratings backed by impressive top-line commercial revenue growth across its rare disease pharmaceutical portfolio.
Evaluating whether Mirum Pharmaceuticals represents a sound investment depends on an investor's tolerance for biotechnology sector volatility.
Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. successfully priced and completed its initial public offering on July 18, 2019, trading under the ticker symbol MIRM on the Nasdaq exchange.
RAPT Therapeutics, Inc. officially completed its initial public offering and began trading its shares on the NASDAQ Global Select Market under the ticker symbol RAPT on October 31, 2019.
Mirum Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the Nasdaq Global Market under the ticker symbol MIRM on July 18, 2019.
Mission Bank is an established regional commercial banking institution maintaining total consolidated assets scaling past $1.0 billion.
Wall Street equity research analysts tracking Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) maintain an overwhelmingly bullish consensus rating, with 12-month average price targets reaching approximately $146.50, and peak estimates extending up to $185.
Evaluating whether to sell your Tonix Pharmaceuticals Holding Corp. (TNXP) stock involves weighing the highly speculative nature of early-stage clinical biotechnology firms against your personal tolerance for extreme market volatility.
Analysts following Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) estimate an average 12-month consensus price target of roughly $146.50 to $147.78, with individual estimates spanning from a conservative low of $125.00 to an optimistic high of $185.00.
Mirum Pharmaceuticals demonstrates rapid top-line sales growth driven by commercialized rare disease medications, but it continues to report substantial net income losses under GAAP metrics due to significant ongoing investments in research, developm...
Mirum Pharmaceuticals cultivates a distinct, patient-centric corporate culture centered around accountability, high performance, and a deep sense of purpose driven by its foundational core values.